Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
Thermo Fisher Scientific (California, USA) has signed an agreement with GE Healthcare (St Giles, UK) to sell business assets for $1.06 billion. Thermo Fisher committed to sell its cell culture, gene modulation, and magnetic beads businesses in 2013 to expedite approval of its pending acquisition of Life Technologies by the European Commission.
The combined revenue of the three businesses, which form part of Thermo Fisher’s Analytical Technologies Segment, is estimated to be $250 million in 2013. Kieran Murphy, president and CEO of GE Healthcare’s Life Sciences division, said: “In addition to providing us with new approaches to drug discovery and biomedical research, this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.” He added: “By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”
For further information visit www.gehealthcare.com
Examining Alkaloid Profiles in Milk with LC-MS
February 10th 2025Research conducted by The Technology Transfer Center of the Edmund Mach Foundation (San Michele all'Adige, Italy) and the University of Udine (Udine, Italy) used liquid chromatography coupled with high-resolution mass spectrometry (LC-MS) to investigate alkaloid transfer from alpine pastures to milk.
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.